ARTV vs. CGON

Last updated Jun 3, 2026

ARTV (Artiva Biotherapeutics, Inc) and CGON (CG Oncology, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, ARTV returned 254.12% vs 108.84% for CGON. At a 0.34 correlation, their price movements are largely independent.

Performance

ARTV vs. CGON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Artiva Biotherapeutics, Inc (ARTV) and CG Oncology, Inc (CGON). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ARTV achieves a 60.14% return, which is significantly higher than CGON's 33.74% return.

ARTV

• 1D: -7.91%
• 1M: -36.39%
• YTD: 60.14%
• 6M: 105.69%
• 1Y: 254.12%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CGON

• 1D: -6.25%
• 1M: -16.21%
• YTD: 33.74%
• 6M: 34.23%
• 1Y: 108.84%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ARTV vs. CGON - Yearly Performance Comparison

	2026 (YTD)	2025	2024
ARTV Artiva Biotherapeutics, Inc	60.14%	-57.44%	-16.00%
CGON CG Oncology, Inc	33.74%	44.77%	-18.57%

Correlation

The correlation between ARTV and CGON is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (All Time) Calculated using the full available price history since Jul 22, 2024	0.34

Fundamentals

Market Cap ARTV : $169.54M CGON : $4.69B
EPS ARTV : -$3.55 CGON : -$1.61
PB Ratio ARTV : 1.93 CGON : 4.30
Total Revenue (TTM) ARTV : $0.00 CGON : $5.07M
Gross Profit (TTM) ARTV : $0.00 CGON : -$2.54M
EBITDA (TTM) ARTV : -$90.10M CGON : -$191.51M

Return for Risk

ARTV vs. CGON — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARTV

ARTV Risk / Return Rank: 87
ARTV Sharpe Ratio Rank: 78
ARTV Sortino Ratio Rank: 91
ARTV Omega Ratio Rank: 87
ARTV Calmar Ratio Rank: 91
ARTV Martin Ratio Rank: 86

CGON

CGON Risk / Return Rank: 87
CGON Sharpe Ratio Rank: 86
CGON Sortino Ratio Rank: 87
CGON Omega Ratio Rank: 82
CGON Calmar Ratio Rank: 90
CGON Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARTV vs. CGON - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Artiva Biotherapeutics, Inc (ARTV) and CG Oncology, Inc (CGON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARTV	CGON	Difference
Sharpe ratio Return per unit of total volatility	1.36	1.93	-0.57
Sortino ratio Return per unit of downside risk	3.41	2.92	+0.49
Omega ratio Gain probability vs. loss probability	1.40	1.33	+0.06
Calmar ratio Return relative to maximum drawdown	5.23	4.68	+0.55
Martin ratio Return relative to average drawdown	9.71	15.68	-5.97
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARTV vs. CGON - Sharpe Ratio Comparison

The current ARTV Sharpe Ratio is 1.36, which is comparable to the CGON Sharpe Ratio of 1.93. The chart below compares the historical Sharpe Ratios of ARTV and CGON, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	ARTV	CGON	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.36	1.93	-0.57
Sharpe Ratio (All Time) Calculated using the full available price history	-0.16	0.29	-0.45

Drawdowns

ARTV vs. CGON - Drawdown Comparison

The maximum ARTV drawdown since its inception was -90.71%, which is greater than CGON's maximum drawdown of -67.47%. Use the drawdown chart below to compare losses from any high point for ARTV and CGON.

Drawdown Indicators

	ARTV	CGON	Difference
Max Drawdown Largest peak-to-trough decline	-90.71%	-67.47%	-23.24%
Max Drawdown (1Y) Largest decline over 1 year	-48.92%	-24.96%	-23.96%
Current Drawdown Current decline from peak	-56.60%	-24.96%	-31.64%
Average Drawdown Average peak-to-trough decline	-58.37%	-25.93%	-32.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.36%	7.45%	+18.91%

Volatility

ARTV vs. CGON - Volatility Comparison

Artiva Biotherapeutics, Inc (ARTV) has a higher volatility of 28.84% compared to CG Oncology, Inc (CGON) at 14.68%. This indicates that ARTV's price experiences larger fluctuations and is considered to be riskier than CGON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARTV	CGON	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.84%	14.68%	+14.16%
Volatility (6M) Calculated over the trailing 6-month period	105.01%	41.79%	+63.22%
Volatility (1Y) Calculated over the trailing 1-year period	187.52%	56.79%	+130.73%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	159.55%	64.24%	+95.31%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	159.55%	64.24%	+95.31%

Dividends

ARTV vs. CGON - Dividend Comparison

Neither ARTV nor CGON has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ARTV and CGON in my portfolio?

ARTV and CGON have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ARTV or CGON?

ARTV has higher volatility (28.84%) compared to CGON (14.68%). In terms of maximum drawdown, ARTV dropped -90.71% vs CGON's -67.47%.

Which has better risk-adjusted returns?

CGON currently has the higher Sharpe Ratio (1.93 vs 1.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.